Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Rate hikes tend to be bad news for ‘jam tomorrow’ sectors but the cycle is ending. Article with Dr. Daniel Koller, Head Investment Management Team BB Biotech, on Portfolio Adviser.

Central banks catch their breath: Will biotech shine again as rates stop rising?

Rate hikes tend to be bad news for ‘jam tomorrow’ sectors but the cycle is ending. Article with Dr. Daniel Koller, Head Investment Management Team BB Biotech, on Portfolio Adviser.
28.09.2023 - Daniel Koller

These investment strategies might interest you

  • BB Biotech AG

    BB Biotech AG (SIX) (CHF)
    ISIN-No.: CH0038389992YTD: 26.76%Active share: 79.47Anzahl Positionen: 22
    Launch date: 16. November 1993